Delivery Order SPE2DB22D1103-SPE2DB24FTQP3

Award Date 8/23/24
Potential Completion Date 8/26/24
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $11,648.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a completion date of October 21, 2024. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $3,983.27 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division. This IDC serves as a primary vehicle for providing a...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,471.20 Firm Fixed Price Delivery Order contract is for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription ophthalmic medication. The contract has an ultimate completion date of January 8, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, to supply RESTASIS 0.05% eye emulsion to the U.S. government. The Delivery Order contract, valued at $4,363.48, was awarded on May 30, 2024 by the Defense Logistics Agency (DLA) Troop Support Medical, with a completion date of May 31, 2024. This contract is not set-aside and is awarded under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $2,526.54 and a completion date of July 10, 2024. It is a Firm Fixed Price Delivery Order contract, with no set-aside designation. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,800.33, is for the delivery of RESTASIS 0.05% eye emulsion 60s, a prescription eye medication. The contract has an ultimate completion date of October 23, 2023 and is a firm fixed-price delivery order. This award is part of Amerisourcebergen's larger Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.80 firm fixed-price delivery order is for the provision of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The contract has an ultimate completion date of March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This federal contract award, valued at $3,080.28, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract is a firm fixed-price Delivery Order, with an ultimate completion date of October 17, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $1,494.15, is a delivery order for RESTASIS 0.05% eye emulsion products. The contract has a firm-fixed price pricing type and an ultimate completion date of March 8, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,496.68 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC...
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB24FTQP3
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor in the United States. The contract, worth $4,235.64, is for the delivery of RESTASIS 0.05% eye emulsion to support federal healthcare programs and providers.

This award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025. This IDC serves as a primary vehicle for AmerisourceBergen to supply a comprehensive range of pharmaceutical and medical products to military treatment facilities and other federal healthcare entities nationwide.

The contract has an ultimate completion date of August 26, 2024 and utilizes a Firm Fixed Price pricing type. No set-aside designation was used for this award.

Generated 11/22/24, 9:48 AM